We designed a phase I clinical trial of escalating doses of topotecan with CY and carboplatin in combination with autologous hematopoietic SCT (AHSCT) for the treatment of relapsed or persistent platinum sensitive ovarian or primary peritoneal carcinoma. After stem cell collection, 16 patients received topotecan at 1.5, 2.5, 3.5, 4.5 or 6.0 mg/m 2 /d combined with CY 1.5 g/m 2 /d and carboplatin 200 mg/m 2 /d, all by 4-day continuous infusion. Steady state pharmacokinetics of topotecan and carboplatin were examined. Pre-treatment biopsies were examined for the expression of topoisomerase (topo) I, Ki67 and Bcl-2 family members by immunohistochemistry. One of six patients at a topotecan dose of 4.5 mg/m 2 /d and two of three patients at 6.0 mg/m 2 /d had dose-limiting toxicity of grade 3 stomatitis lasting 42 weeks. There was no treatment-related mortality. As topotecan clearance was constant over the dose range examined, topotecan steady state plasma concentrations increased with dose. Median progression-free survival and overall survival were 6.5 months and 2.7 years, respectively. Shorter progressionfree survival was observed in tumors with low topo expression (P ¼ 0.04). Topotecan can safely be dose escalated to 4.5 mg/m 2 /d in combination with CY, carboplatin and AHSCT. This trial is registered at ClinicalTrials.gov as NCT00652691.
Introduction
Ovarian cancer is the second most common female pelvic malignancy. 1 Despite the ability of treatment to produce states of minimal residual disease, recurrence and death are common; and 5-year survival rates for patients with advanced disease are 35-40%. 1, 2 Studies in hematologic malignancies have demonstrated that high-dose chemotherapy (HDC) with autologous hematopoietic SCT (AHSCT) can cure or prolong survival. 3, 4 Cohort studies of women diagnosed with persistent or relapsed ovarian cancer have reported long-term disease control with HDC-AHSCT. [5] [6] [7] [8] More recent studies, however, have questioned whether HDC-AHSCT confers any benefit compared with conventional chemotherapy. 9, 10 Neither of these two studies 9,10 used topotecan, a topoisomerase (topo) I inhibitor that has been used in several previous transplantation regimens, [11] [12] [13] [14] [15] [16] [17] [18] and is active in relapsed and refractory ovarian cancer but induces dose-limiting hematological toxicity in the non-transplant setting. [19] [20] [21] A series of pre-clinical investigations have suggested that the antiproliferative effects of topotecan and platinating agents, such as carboplatin, are synergistic in vitro [22] [23] [24] and in vivo. 25 On the basis of these results as well as the previously demonstrated efficacy of topotecan, carboplatin and CY as single agents in ovarian cancer, the activity of the topotecan-carboplatin and topotecan-CY doublets in clinical studies, and the observation that topotecan can safely be dose escalated, we designed a phase I clinical trial combining escalating doses of topotecan with CY and carboplatin in an attempt to develop a more effective HDC regimen for the treatment of relapsed and persistent ovarian carcinoma. This study was designed to enroll patients who have been shown in previous studies to be most likely to respond to this modality of therapy. 6 In conjunction with this study, we examined the steady-state pharmacokinetics of high-dose topotecan and carboplatin, as well as pre-treatment expression of polypeptides that have been reported to affect the response to topotecan and DNA damaging agents in pre-clinical models.
Patients and methods

Patients
Women 18-70 years of age with relapsed or persistent platinum sensitive epithelial ovarian cancer, or primary peritoneal cancer were enrolled between September 1998 and April 2002. Relapsed platinum-sensitive ovarian carcinoma was defined as histologically documented recurrence with or without rising CA125 levels 46 months after initial platinum-based chemotherapy. Persistent platinum-sensitive ovarian cancer was defined as a positive second-look laparotomy in patients with normalization of CA125 after platinum-based chemotherapy. In patients with relapsed platinum-sensitive cancer the disease was less than 2 cm in greatest dimension at the time of transplantation. Some patients underwent a debulking procedure to achieve this. All patients provided written informed consent to the Institutional Review Board which approved the study.
PBSC collection, HDC and transplantation
Therapy was based on the STAMP V HDC-AHSCT regimen for breast cancer 26 except that topotecan was substituted for thiotepa. The doses of carboplatin given to the patients in this study were calculated in mg/m 2 rather than by the area under the curve method, as this is how the dosing was done in the STAMP V regimen. Patients were allowed to receive additional chemotherapy after debulking surgery if there were delays in obtaining insurance approval for HDC-AHSCT. All patients underwent re-staging of their disease within 30 days before transplant. For stem cell mobilization, patients received granulocyte-colony stimulating factor 10 mg/kg subcutaneously daily until leukapheresis yielded a minimum of 2 Â 10 6 CD34 þ cells/kg. Patients who did not mobilize well were allowed to undergo autologous BM harvest. After recovery from harvest, patients received a 4-day continuous i.v. infusion of carboplatin, 200 mg/m 2 /d (total dose 800 mg/m 2 ) and CY, 1500 mg/m 2 /d (total dose 6000 mg/m 2 ), along with an assigned dose of topotecan. The initial dose level of topotecan was 1.5 mg/m 2 /d (total dose 6.0 mg/m 2 ) with subsequent planned dose levels of 2.5, 3.5, 4.5, 6.0, 7.5 and 9.0 mg/m 2 /d in an accelerated titration schedule. Beginning on day þ 6 post-AHSCT, granulocyte macrophage-colony stimulating factor 5 mg/kg/d was administered until an ANC 40.5 Â 10 9 /l was maintained for two consecutive days.
On day 100 post transplantation, every 3 months in years 1-2 and then biannually years 2-5 until progression, patients underwent a physical examination that included a complete blood count, blood chemistry profile, CA125 measurement, a tumor assessment and a toxicity assessment. Patients who refused further treatment or discontinued treatment because of toxicity were followed annually for toxicity, progression and death.
Pharmacokinetic analyses
Topotecan and unbound platinum were analyzed in blood samples (2 Â 7 ml) drawn before and at 24, 48, 72 and 96 h of chemotherapy infusion. Plasma was prepared within 20 min of blood collection and immediately ultrafiltered (for free platinum) or frozen at À70 1C until analyzed for topotecan. Total topotecan and ultrafilterable platinum were assayed as described. 27 The steady-state plasma concentrations, C ss , were calculated as the average of 24-96 h plasma concentrations. The steady-state clearance, CL ss , was calculated by dividing the dose rate by the C ss value. CL ss values for carboplatin were corrected for the MWs of carboplatin (371.25 g/mol) and platinum (195.1 g/mol).
Immunohistochemical analysis of pre-transplant tumor samples
Pre-treatment biopsies were analyzed for topo I, MIB-1, Bcl-2, Bcl-x L , Mcl-1, Bax and p53 by immunohistochemistry. In brief, a tissue microarray was constructed from the most recent biopsy specimen obtained before trial enrollment. Sections (4 mm thick) were deposited on slides; deparaffinized; rehydrated in ethanol; and incubated for 10 min at room temperature in 3% H 2 O 2 in methanol to inactivate endogenous peroxidases. After microwave-induced Ag retrieval (30 min in 0.01 M citric acid, pH 6.0), slides were stained using commercially available antibodies and standard immunoperoxidase methods in the Tissue and Cell Molecular Analysis Shared Resource of the Mayo Clinic Cancer Center. Digital images captured with a Bliss 'Virtual Microscopy' microscope were visually examined by an investigator who was blinded to the patient outcome; and the intensity of staining of tumor cells was graded as negative (0), weak (1 þ ), moderate (2 þ ) or strong (3 þ ). The percentage of positively stained ovarian cancer cells in each image was also estimated. Values presented are the mean of the three cores on the tissue microarray whenever possible.
Statistical considerations
The primary objective was to determine the maximum tolerated dose of topotecan when used in combination with high dose CY and carboplatin. Dose-limiting toxicities (DLTs) were defined to be grade 4 hematological toxicities lasting 48 weeks, mucositis resulting in aspiration pneumonia or requiring either preventive intubation or parenteral narcotics and/or nutrition for 414 days, and any unexpected grade 3 þ non-hematological toxicity that could not be well controlled or did not improve after 2 weeks duration. These levels of toxicities were chosen so as not to prematurely terminate the dose escalation schedule of topotecan as a result of a less severe toxicity.
As topotecan had been successfully dose escalated in a previous transplantation study up to the equivalent of 5 mg/m 2 /d by continuous infusion, 11 an accelerated titration approach was used. A minimum of one or a maximum of six patients were to be enrolled onto the first three dose levels and a minimum of two to a maximum of six patients were to be enrolled onto all subsequent dose levels. The serious adverse events that triggered a change in the dose escalation schedule from one patient per dose level to three patients per dose level were grade 42 non-hematological toxicities except grade 3/4 infection/febrile neutropenia, vomiting, stomatitis, petechiae/purpura or vaginal bleeding and grade 4 BM engraftment or peripheral stem cell toxicity. If no serious adverse events were reported among the patients enrolled on the first three dose levels, then the fourth dose level and all subsequent dose levels would initially treat three patients.
Time to progression was defined as the time from registration to disease progression. Patients who died without documentation of progression were considered to have progressed on the date of their death. Survival was measured from registration to death. Times to event distributions were estimated using the Kaplan-Meier method. Wilcoxon's rank-sum tests were used to assess whether time to progression or survival time differed with respect to disease site.
Results
Clinical outcomes
As indicated in Table 1 , a total of 16 patients, 10 (62%) with ovarian carcinoma at diagnosis and 6 (38%) with primary peritoneal carcinoma, were enrolled in this study. At initial diagnosis 1 patient had stage II disease, 11 stage IIIC and 4 stage IV disease. The median age at enrollment was 51 years (range 38-63).
All patients were required to have platinum-sensitive disease. In 11 patients, disease was microscopic or at most a few millimeters in size at second look laparotomy after six or more cycles of paclitaxel-and platinum-based i.v. chemotherapy. Four others had relapsed with disease-free intervals of 6, 9, 24 and 26 months after an initial regimen of paclitaxel-and platinum-based treatment. One additional patient was found to be ineligible after enrollment, as her disease-free interval was only 2 months. Three of the five patients who relapsed had a secondary optimal debulking procedure before the transplantation. Of the 14 patients (11 patients with persistent disease and 3 patients with relapsed disease) who had surgery before HDC-AHSCT, no visible disease was left after laparotomy in 5 patients and residual nodules of a few millimeters or less were left in 9 patients. The other two patients had no surgery immediately before the transplantation, as one had no measurable disease by clinical examination or computed tomography scan of the abdomen and pelvis and the other had a less than one cm area of abnormality on computed tomography scan.
Eight patients had additional paclitaxel and platinumbased chemotherapy after registration while awaiting insurance approval for transplantation and not for purposes of tumor debulking. Of these 8 patients, 5 had one cycle and 1 each had two, three and four cycles.
During administration of the conditioning regimen, carboplatin was administered as 200 mg/m 2 /day, which translated to areas under curves ranging from 2.7 to 4.2 (median ¼ 3.24) ( Table 1) . Topotecan doses were escalated from 1.5 mg/m 2 /day to 6.0 mg/m 2 /day. One patient was treated at the 1.5 mg/m 2 /day dose level without DLT. As the first patient treated at 2.5 mg/m 2 /day developed grade 4 emesis, albeit for o14 days, the accelerated dose escalation was terminated. Among two additional patients treated at 2.5 mg/m 2 /day, three at 3.5 mg/m 2 /day dose level and six at 4.5 mg/m 2 /day, there was a single DLT (grade 3 stomatitis lasting 414 days). In contrast, two of three patients at 6.0 mg/m 2 /day had DLTs consisting of severe stomatitis requiring parenteral nutrition and narcotics for 414 days. Thus, the maximum tolerated dose and recommended phase II dose is topotecan 4.5 mg/m 2 /day along with carboplatin 200 mg/m 2 /day and CY 1500 mg/m 2 /day, all by continuous 4-day infusion.
All 16 patients had grade 4 hematological toxicity and grade 3 febrile neutropenia. Of the 13 patients who developed grade 3 stomatitis, 3 patients had cases so severe that they were considered dose limiting. Other serious adverse events are presented in Table 2 and were typical of those seen with AHSCT.
The median times to neutrophil engraftment and plt count 450 Â 10 9 /l were 11 days (range: 10-20) and 18 days (range: 14-24), respectively. Three patients required a BM harvest because of inadequate PBSC harvest, but all three engrafted well post transplant.
At day 100 post transplant, five patients had a complete response to treatment based on normalization of their CA125 level and/or resolution of computed tomography scan abnormalities, one demonstrated regression of disease, six were stable and four had already progressed.
All 16 patients died with progression of disease. The observed median PFS was 6.5 months, with 1-year PFS rate of 31% (95% CI: 15-65%). The median OS was 2.7 years. Because of the excellent recovery of blood counts after transplantation, patients who relapsed were able to tolerate additional salvage chemotherapy. Of the 15 patients with adequate follow up post-relapse, the median no. of regimens of cytotoxic chemotherapy administered was five (range 0-9).
The observed median PFS and median OS was 7.9 months and 3.3 years, respectively, among women with ovarian carcinoma (n ¼ 10) and 4.8 months and 2.3 years, respectively, among the women with primary peritoneal carcinoma (n ¼ 6). As expected, neither PFS (P ¼ 0.368) nor OS (P ¼ 0.712) were found to differ with respect to primary disease site.
Pharmacokinetic analysis
Steady state pharmacokinetics of total topotecan were evaluated for all 16 patients (Table 3 ). Topotecan CL ss was similar over the dose range examined (Spearman's rank correlation coefficient ¼ 0.02), with a median value of 184 ml/min/m 2 (range: 104-1068 ml/min/m 2 , Table 3 ). Accordingly, the topotecan C ss tended to increase with topotecan dose (Spearman's rank correlation coefficient ¼ 0.57, Figure 1a ).
The carboplatin CL ss likewise was similar over the topotecan dose range examined (Spearman's rank correlation coefficient ¼ À0.07, Figure 1b) , with a median value of 62 ml/min/m 2 (range: 50-81 ml/min/m 2 , Table 3 ). These pharmacokinetic parameters were similar to those reported in other clinical trials. [27] [28] [29] There was no evidence of a significant association between steady-state free platinum levels and PFS (Spearman's rank correlation coefficient ¼ À0. 16 ). 
Analysis of pre-transplant tumor specimens for topo I and other polypeptides implicated in topotecan resistance
Previous studies have identified a number of factors that can affect topotecan sensitivity in pre-clinical models. These include cell cycle progression 30, 31 and levels of the target enzyme topo I. 31, 32 In addition, recent studies have demonstrated that platinated DNA acts like a topo I poison to trap covalent topo-DNA complexes, 33 leading to the suggestion that decreased topo I content might diminish sensitivity to cisplatin and topotecan. Moreover, the expression of antiapoptotic Bcl-2 family members, such as Bcl-2 and Bcl-x L , has been reported to affect sensitivity to topotecan and DNA cross-linking agents. 34, 35 Accordingly, we analyzed Ki67 staining (a marker of proliferation) with the Ab MIB-1 and topo I staining as well as the expression of Bcl-2 family members, such as Bcl-2, Bcl-x L , Mcl-1 and Bax, by immunohistochemistry. Results of this analysis are summarized in Table 4 . Fourteen of 16 enrolled patients had a pre-registration biopsy specimen available for analysis. We observed that tumors with weak (1 þ ) or undetectable topo I had a median time to progression of 4.3 months (n ¼ 5), whereas tumors with readily detectable topo I staining (2 þ or 3 þ intensity) had a median time to progression of 13.2 months (n ¼ 9, Wilcoxon's rank-sum test P ¼ 0.042). There was also a modest positive correlation between the percentage of Mib-1 positive cells and PFS time (Spearman's rho ¼ 0.47, P ¼ 0.09). Strong staining intensity was seen with Bax in all 14 pre-treatment biopsies and with Bcl-x L in 13 (93%). Undetectable or weak staining was seen with Bcl-2 in 13 (93%) samples and with Mcl-1 in 9 (65%).
Discussion
In this study, we were able to successfully dose escalate topotecan to 4.5 mg/m 2 /day (total dose 18 mg/m 2 ) for 4 days in combination with CY and carboplatin. The vast majority of patients had undergone optimal debulking surgery of their tumor before transplantation. As anticipated from the results of studies of topotecan in leukemia patients, the DLT was severe mucositis requiring parenteral nutrition and narcotics for more than 2 weeks. Based on this DLT at 6.0 mg/m 2 /day, the maximum tolerated dose is 4.5 mg/m 2 /day. The regimen was otherwise generally well tolerated. All patients achieved neutrophil and plts engraftment in a timely manner, despite the fact that three patients required BM harvest. Although all patients have subsequently had disease progression, four patients survived more than 4 years after the transplantation. With the excellent recovery of blood counts after transplantation, Table 2 Severe toxicities topotecan dose in mg/m 2 /day -BMT  1  3  3  6  3  Grade 3/4 Neutropenia-BMT  1  3  3  6  3  Grade 3/4  Thrombocytopenia-BMT   1  3  3  6  3   Grade 3/4 Anemia  1  3  3  4  3  Grade 3 Febrile Neutropenia  1  3  2  6  3  Grade 3/4 Infection-ANC  0  0  0  0  2  Grade 3/4 Anorexia  1  3  2  4  3  Grade 3 Stomatitis  0  2  2  6  3  Grade 3 Dehydration  0  1  0  3  0  Grade 3 Epistaxis  0  0  0  2  3  Grade 3 Infection-Catheter  1  2  0  1  0  Grade 3 Hemorrhage-Thrombosis   0  0  0  2  0   Grade 3 Hypokalemia  0  1  1  2  2  Grade 3 Hyponatremia  0  2  0  1  1  Grade 3 Infection-Catheter  1  2  0  1  0  Grade 3 Nausea  1  1  1  2  3  Grade 3 SGOT  0  0  0  2  1  Grade 3 SGPT  0  0  0  2  0  Grade 3 Syncope  0  0  0  0  2 Abbreviations: SGOT ¼ aspartate aminotransferase; SGPT ¼ alanine aminotransferase. many patients were able to tolerate and respond to salvage chemotherapy as has been shown by others. 36 Topotecan CL ss was similar over the dose range administered. As a result, topotecan C ss increased as the topotecan dose increased. Carboplatin CL ss was also similar at all dose levels. In contrast to cisplatin, which diminishes topotecan clearance, 37 we did not detect a significant pharmacokinetic interaction between topotecan and carboplatin. These results are consistent with a recent report that carboplatin does not affect topotecan clearance in leukemia patients. 27 Examination of a variety of parameters in pre-treatment ovarian cancer specimens indicated that low or absent staining for topo I, the target of topotecan, was associated with rapid progression. This correlation is consistent with the known relationship between topo I content and topotecan sensitivity observed in model systems. 31, 32 Although topotecan was only one of three agents administered in this trial, it is important to note that platinated DNA 33 and other DNA lesions 38 have been reported to trap topo I-DNA covalent complexes. For topotecan and certain DNA damaging agents, diminished topo I expression has been associated with resistance in pre-clinical models, providing a potential explanation for the shortened disease-free survival in the present patients with tumors that expressed little or no topo I. Although two previous studies failed to observe any relationship between topo I expression and response of ovarian cancer patients to cisplatin-based therapy, 39, 40 the present study differed from the earlier ones by examining topo I polypeptide levels rather than mRNA and by specifically focusing on cancer cells rather than tumor samples containing both neoplastic epithelium and stroma. Further study is required to determine whether diminished topo I content correlates with resistance to other topotecan-or platinum-based ovarian cancer regimens.
Multiple phase I trials have reported the administration of escalating doses of topotecan in combination with etoposide, ifosfamide, carboplatin, paclitaxel, and/or thiotepa, demonstrating the feasibility of this approach with acceptable toxicity and modest response rates. [11] [12] [13] [14] [15] [16] [17] [18] The present study extends these observations to a topotecancarboplatin-CY regimen that contains three agents known to have activity in ovarian cancer.
The role of autologous transplant in the treatment of ovarian carcinoma remains uncertain. A pilot study of 0  0  2  3  3  2  28.5  3  13  3  3  1  3  3  3  5.3  2  33  3  1  1  3  3  4  8.7  3  6  2.5  0  1  3  3  5  5.9  3  45  3  0  1  2  3  8  4.3  0  40  3  0  1.5  3  3  9  7.1  0  5  0  1  1  3  3  10 11 .6  0  25  3  0  1  3  3  11  5.0  2  0  3  0  1  3  3  12  21.4  2  45  3  1  3  3  3  13 2.2 0.5 0 0 1. 5  3  3  3  14 13. Ultrafilterable Pt C ss (ng/ml) 0.00 2.00 4.00 6.00 8.00 0.00 2.00 4.00 6.00 8.00 three cycles of high dose carboplatin and paclitaxel followed by a high-dose of melphalan with AHSCT demonstrated only one pathological complete response out of nine patients treated. 41 A trial of 110 patients with advanced ovarian carcinoma (9 patients in stage III and 101 patients in stage IV) randomized after second-look laparotomy to receive either a high-dose of carboplatin and cyclophosphamide with AHSCT or conventional maintenance chemotherapy with carboplatin and cyclophosphamide 9 demonstrated median disease-free survival and OS of 12 and 43 months in the conventional chemotherapy arm and 18 (P ¼ 0.22) and 50 (P ¼ 0.43) months in the highdose chemotherapy arm. Another trial that randomized 149 patients after optimal debulking surgery to 6 cycles of carboplatin þ paclitaxel vs 2 cycles of paclitaxel þ cyclophosphamide followed by 3 cycles of high-dose carboplatin and paclitaxel with melphalan added to the third cycle demonstrated OS of 63 months in the standard chemotherapy arm compared with 54 months in the highdose arm. 10 In view of the activity of topotecan, carboplatin and CY in ovarian cancer, we had hoped that the current regimen would yield longer PFS. The lack of long-term PFS, even at the highest doses, was disappointing. Accordingly, while we have defined a maximum tolerated dose for this regimen, this lack of long-term PFS, along with the lack of benefit of AHSCT in the randomized trials cited above, have prompted us to defer pursuing a phase II trial of this regimen at this time and further indicates that there are little or no data to support the use of AHSCT in the treatment of ovarian cancer outside of clinical trials. Nevertheless, we have demonstrated the feasibility of doseescalating topotecan in the setting of AHSCT in combination with carboplatin and CY and this may have applicability in other tumor settings.
